Quick Answer
Structure Therapeutics Inc. reported Diluted EPS of $0.80 per share (loss) for fiscal year 2025.
Structure Therapeutics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.80 | -2.6% |
| 2024 | -$0.78 | +3.7% |
| 2023 | -$0.81 | +85.3% |
| 2022 | -$5.51 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.37 | -85.0% | -37.0% |
| March 31, 2025 | -$0.27 | -42.1% | -35.0% |
| September 30, 2024 | -$0.20 | +4.8% | -11.1% |
| June 30, 2024 | -$0.18 | +10.0% | +5.3% |
| March 31, 2024 | -$0.19 | +24.0% | +9.5% |
| September 30, 2023 | -$0.21 | +83.5% | -5.0% |
| June 30, 2023 | -$0.20 | +87.8% | +20.0% |
| March 31, 2023 | -$0.25 | +82.6% | +80.3% |
- Structure Therapeutics Inc. showed a decrease of -2.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Structure Therapeutics Inc.’s diluted eps has grown by 85.5% (from $5.51 per share (loss) to $0.80 per share (loss)).
- The most recent figure is from Structure Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: